NCT04892134|Unknown
Loading search results
Sponsor study identifier
observational
500
1 country
1
Study Start
October 3, 2019
Actual (reported)Primary Completion
October 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 3, 2019
Actual (reported)May 4, 2021
Actual (reported)May 19, 2021
Actual (reported)October 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prediction of EDSS ( Expanded Disability Status Scale) progression by combined markers of the disease
EDSS score
a maximum of 4 years
Prediction of clinical relapses
a maximum of 4 years
Conversion from CIS (Clinically Isolated Syndrome) to MS (Multiple Sclerosis) defined by MRI and clinical criteria
a maximum of 4 years
Time of transition to progressive form of MS
a maximum of 4 years
Neuropsychological progression (decrease in SDMT performance)
a maximum of 4 years
Increase in morphological damage (lesion load, atrophy)
a maximum of 4 years
40-50 ml of blood is taken
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Participants are patients who are in inpatient or outpatient care of the Department of Neurology at the Medical University of Graz, Austria with suspected or proven multiple sclerosis
Medical University of Graz
Graz, Styria, 8010, Austria
Hechenberger S, Broeders TAA, Bet MDA, Helmlinger B, Tinauer C, Ropele S, Heschl B, Wurth S, Damulina A, Khalil M, Schoonheim MM, Enzinger C, Pinter D. Time-Varying Brain Functional Reconfiguration Patterns Associated With Fatigue in Multiple Sclerosis. Hum Brain Mapp. 2026 Mar;47(4):e70480. doi: 10.1002/hbm.70480.
serum, plasma, peripheral blood mononuclear cells, DNA, urine
Christian Enzinger, Prof
Medical University of Graz
First Submitted
May 4, 2021
First Posted
May 19, 2021
Study Start
October 3, 2019
Actual (reported)Primary Completion
October 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
Contact the study team to confirm eligibility.
Study Completion
October 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 19, 2023
Record last verified: 2023-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: